Positive BCL2L12 expression predicts favorable prognosis in patients with laryngeal squamous cell carcinoma.
CONCLUSIONS: BCL2L12 protein expression could be used as a favorable prognostic tissue biomarker in patients with primary advanced-stage LSCC. On the contrary, BCL2 and BAX did not correlate with prognosis in patients with primary LSCC.
PMID: 31104007 [PubMed - as supplied by publisher]
Source: Cancer Biomarkers - Category: Cancer & Oncology Tags: Cancer Biomark Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Head and Neck Cancer | Laryngeal Cancer | Skin Cancer | Squamous Cell Carcinoma | Study